588 related articles for article (PubMed ID: 19799470)
1. Financial risk of the biotech industry versus the pharmaceutical industry.
Golec J; Vernon JA
Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
[TBL] [Abstract][Full Text] [Related]
2. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
Golec J; Vernon JA
Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
[TBL] [Abstract][Full Text] [Related]
3. Just how good an investment is the biopharmaceutical sector?
Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
[TBL] [Abstract][Full Text] [Related]
4. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Reed SD; Califf RM; Schulman KA
Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
[TBL] [Abstract][Full Text] [Related]
5. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
Billette de Villemeur E; Versaevel B
J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
[TBL] [Abstract][Full Text] [Related]
6. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
7. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
Gascón F; Lozano J; Ponte B; de la Fuente D
Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
[TBL] [Abstract][Full Text] [Related]
8. How Indian biotech is driving innovation.
Nogrady B
Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
[No Abstract] [Full Text] [Related]
9. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
10. Microcap pharmaceutical firms: linking drug pipelines to market value.
Beach R
J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
[TBL] [Abstract][Full Text] [Related]
11. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
D'Este P; Tribó JA; García-Romero A
Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
[TBL] [Abstract][Full Text] [Related]
12. Biotech firms jump on SARS bandwagon.
Basu P
Nat Biotechnol; 2003 Jul; 21(7):720. PubMed ID: 12833076
[No Abstract] [Full Text] [Related]
13. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
[TBL] [Abstract][Full Text] [Related]
14. How does capital structure change product-market competitiveness? Evidence from Chinese firms.
Li L; Wang Z
PLoS One; 2019; 14(2):e0210618. PubMed ID: 30721237
[TBL] [Abstract][Full Text] [Related]
15. Outlook: directed development: catalysing a global biotech industry.
Sun A; Perkins T
Nat Rev Drug Discov; 2005 Sep; 4(9):719-25. PubMed ID: 16138105
[TBL] [Abstract][Full Text] [Related]
16. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
Bardey D; Bommier A; Jullien B
J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
[TBL] [Abstract][Full Text] [Related]
17. Biotech firms look for virtual success.
Schmidt C
Cancer Discov; 2012 Jan; 2(1):OF5. PubMed ID: 22585175
[No Abstract] [Full Text] [Related]
18. A venture capital view of challenges, opportunities, and innovation in biomedical research.
Ratcliffe LT
Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
[TBL] [Abstract][Full Text] [Related]
19. Intellectual Capital and Financial Performance: Comparison With Financial and Pharmaceutical Industries in Vietnam.
Zhang XB; Duc TP; Burgos Mutuc E; Tsai FS
Front Psychol; 2021; 12():595615. PubMed ID: 33841234
[TBL] [Abstract][Full Text] [Related]
20. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
Danzon PM; Nicholson S; Pereira NS
J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
